64 Dulaglutide was approved for marketing in the U.S
It is a first-in-class triple hormone receptor agonist, designed as a single molecule that simultaneously activates three distinct receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG)
Several GLP-1 and dual GIP/GLP-1 receptor agonists have been developed to harness these pharmacological effects in the treatment of type 2 diabetes, with some demonstrating robust effectiveness in weight management and prevention of cardiovascular diseases
The frequency of the injections will be determined based on your health status and overall condition
Dairy Free Gluten Free Soy Free Non-GMO Preservative Free Corn Free
These factors, along with proven efficacy in glycemic control, weight management, and cardiovascular risk reduction, make Europe a key region for the growth and adoption of GLP-1 therapies